| Vol. 6.04 – 4 February, 2022 |
| |
|
|
| Researchers combined cell-type-resolved genomics and computational approaches to map crosstalk between hepatocytes and liver macrophages during fasting. [Cell Metabolism] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Formyl peptide receptor 2 (FPR2) was more highly expressed in hepatocytes and healthy livers from females than males, and FPR2 deletion exacerbated liver damage in choline-deficient, L-amino acid-defined, high-fat diet-fed female mice. [Nature Communications] |
|
|
|
| In vitro knockdown of either cullin 1 or cullin 3, but not other cullin members, attenuated insulin-induced insulin receptor substrate protein degradation and enhanced cellular insulin signaling activation. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors explored the biological function and clinical significance of the m6A methyltransferase METTL3 in intrahepatic cholangiocarcinoma (ICC) and revealed that METTL3 was upregulated and predicted poor prognosis of patients with ICC. [Oncogene] |
|
|
|
| To investigate the role of myeloid cell MANF in the pathogenesis of acetaminophen-induced liver injury (AILI), scientists assayed serum and liver samples from AILI model mice and patients with drug-induced liver injury. [Cell Death & Disease] |
|
|
|
| Researchers identified an HCC-related lncRNA, CMB9-22P13.1, which was highly expressed and correlated with advanced stage, vascular invasion, and poor survival in HCC. [Cell Death & Disease] |
|
|
|
| Investigators described a robust, scalable protocol that allowed them to consistently generate high-quality bipotent human hepatoblasts and hepatocyte-like cells from both embryonic stem cells and induced pluripotent stem cells. [Stem Cell Reports] |
|
|
|
| The authors generated a doxycycline-inducible MHC-I and II antigen-expressing HCC cell line which allowed them to investigate tumor antigen-specific T cell response in two non-alcoholic fatty liver disease (NAFLD) mouse models. [iScience] |
|
|
|
| Scientists combined single-cell transcriptomic, proteomic, and chromatin accessibility data to investigate how heterogeneous phenotypes contributed to metastatic potential in five HCC cell lines. [iScience] |
|
|
|
| Investigators reported a new approach that enabled the formation of self-assembled 3D spheroids of adipose-derived stem cells and murine hepatocytes via reconstituted collagen fibers. [Scientific Reports] |
|
|
|
| Researchers analyzed angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 expression and localization in human liver cancers and in non-tumor livers. [Scientific Reports] |
|
|
|
| The authors investigated melatonin’s antitumor molecular mechanisms to inhibit the proliferation of HepG2 cells. [Heliyon] |
|
|
|
| Using a candidate gene approach, researchers identified a locus at the Pleckstrin and Sec7 domain-containing 3 (PSD3) gene resulting in a leucine to threonine substitution at position 186 of the protein that reduced susceptibility to the entire spectrum of fatty liver disease in individuals at risk. [Nature Metabolism] |
|
|
|
|
| Investigators summarize the recent progress on the roles and mechanisms of necroptosis and focus on the crosstalk between necroptosis and the other pathogenesis of alcoholic liver disease (ALD), providing a theoretical basis for targeting necroptosis as a novel treatment for ALD. [Cell Proliferation] |
|
|
|
| Mitochondrial dysfunction and damage induced by overnutrition lead to oxidative stress, inflammation, liver cell death, and collagen production, which advance hepatic steatosis to nonalcoholic steatohepatitis (NASH). [Acta Pharmacologica Sinica] |
|
|
|
|
| Liver Institute Northwest is enrolling participants into RESPONSE, a global Phase III clinical research study evaluating the safety and efficacy of seladelpar, a drug for people diagnosed with PBC who have been using ursodeoxycholic acid but have not achieved the recommended treatment goal. [Liver Institute Northwest (Biospace, Inc.)] |
|
|
|
| NorthSea Therapeutics B.V. announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of intestinal failure associated liver disease. [NorthSea Therapeutics B.V.] |
|
|
|
|
| March 9 – 11, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| Mayo Clinic – Rochester, Minnesota, United States |
|
|
|
| University of Vermont – Burlington, Vermont, United States |
|
|
|
| University of Texas Medical Branch – Galveston, Texas, United States |
|
|
|
| Center for Cooperative Research in Biosciences – Derio, Spain |
|
|
|
| NIH National Institute on Alcohol Abuse and Alcoholism – Bethesda, Maryland, United States |
|
|
|
|